FrancophonIA/ELRC3.0 huggingface dataset:
English: Sixty eight percent (21/31) of infliximab-treated patients receiving a 5 mg/kg dose regimen achieved a clinical response vs. 26% (8/31) placebo-treated patients (p = 0.002).
Croatian: Klinički odgovor postiglo je 68% bolesnika (21/31) liječenih infliksimabom u dozi od 5 mg/kg naspram 26% bolesnika (8/31) koji su primali placebo (p = 0,002).
English: Fistulising, active Crohn's disease
Croatian: Fistulirajuća, aktivna Crohnova bolest
English: In rheumatoid arthritis patients who received the recommended repeated treatment dose regimens with methotrexate, 8% of patients developed antibodies to infliximab.
Croatian: Protutijela na infliksimab razvila su se u 8% bolesnika s reumatoidnim artritisom koji su liječeni po preporučenom režimu ponavljane primjene s metotreksatom.
English: p < 0.001, for each infliximab treatment group vs. placebo.
Croatian: 30. tjednu p < 0,001 za svaku skupinu liječenu infliksimabom u usporedbi s placebom.
English: Juvenile rheumatoid arthritis
Croatian: Juvenilni reumatoidni artritis
English: The safety and efficacy of Remicade have not been studied in children with ulcerative colitis below the age of 6 years.
Croatian: Sigurnost i djelotvornost lijeka Remicade u djece mlađe od 6 godina koja boluju od ulceroznog kolitisa nisu ispitivani.
English: Re-administration for psoriatic arthritis
Croatian: Ponovna primjena u psorijatičnom artritisu
English: During the 16-week double-blind phase, patients received either 5 mg/kg infliximab or placebo at weeks 0, 2, 6, and 14 (52 patients in each group).
Croatian: Tijekom 16 tjedana dvostruko slijepe faze ispitivanja, bolesnici su primali ili infliksimab u dozi od 5 mg/kg ili placebo u 0., 2., 6. i 14. tjednu (52 bolesnika u svakoj skupini).
English: After reconstitution one ml contains 10 mg of infliximab.
Croatian: Nakon rekonstitucije, jedan ml sadrži 10 mg infliksimaba.
English: Infliximab (week 54)
Croatian: Infliksimab (54. tjedan)
English: There were 95 subjects from group 2 who continued on 5 mg/kg every 6 weeks.
Croatian: U skupini 2 je 95 ispitanika nastavilo primati infliksimab u dozi od 5 mg/kg svakih 6 tjedana.
English: Tuberculosis, bacterial infections, including sepsis and pneumonia, invasive fungal, viral, and other opportunistic infections have been observed in patients receiving Remicade.
Croatian: U bolesnika liječenih infliksimabom opažene su tuberkuloza, bakterijske infekcije uključujući sepsu i pneumoniju, invazivne gljivične, virusne i druge oportunističke infekcije.
English: Median follow-up (wks)
Croatian: Medijan praćenja (tjedni)
English: The antibody titres were notably higher for the 3 mg/kg compared to the 6 mg/kg group.
Croatian: Titar protutijela bio je zamjetno viši u skupini koja je primala dozu od 3 mg/kg u odnosu na skupinu koja je primala dozu od 6 mg/kg.
English: Signs include a fever, feeling tired, (persistent) cough, shortness of breath, weight loss, night sweats, diarrhea, wounds, dental problems, burning when urinating or ‘flu-like' signs.
Croatian: Ti znakovi uključuju vrućicu, umor, (ustrajan) kašalj, nedostatak zraka, gubitak tjelesne težine, noćno znojenje, proljev, rane, probleme sa zubima, žarenje pri mokrenju ili simptome nalik gripi.
English: Patients received placebo, 3 mg/kg or 10 mg/kg infliximab at weeks 0, 2 and 6, and then every 4 or 8 weeks thereafter.
Croatian: Bolesnici su primili ili placebo ili infliksimab u dozi od 3 mg/kg odnosno 10 mg/kg 0., 2. i 6. tjedna ispitivanja, a zatim svakih 4 ili 8 tjedana.
English: • Fainting
Croatian: • nesvjestica
English: Current administrations:
Croatian: Trenutni režim primjene lijeka:
English: Dizziness may occur following administration of Remicade (see section 4.8).
Croatian: Nakon primjene lijeka Remicade može nastupiti omaglica (vidjeti dio 4.8).
English: No major age- or weight-related differences in clearance or volume of distribution were observed in rheumatoid arthritis patients.
Croatian: Nisu opažene veće razlike u klirensu i volumenu distribucije s obzirom na dob i tjelesnu težinu bolesnika s reumatoidnim artritisom.
English: Infliximab (week 24)
Croatian: Infliksimab (24. tjedan)
English: Infliximab (week 16)
Croatian: Infliksimab (16. tjedan)
English: If a patient does not respond by 6 weeks (i.e. after 2 doses), no additional treatment with infliximab should be given.
Croatian: Ako bolesnik ne odgovori na terapiju nakon 6 tjedana (tj. nakon 2 doze), ne bi trebalo nastaviti liječenje infliksimabom.
English: 5 vials 100 mg
Croatian: 5 bočica sa 100 mg
English: Absence of any draining fistulas.
Croatian: Nisu prisutne fistule iz kojih se cijedi sadržaj.
English: Tell your doctor straight away if you get new or worsening signs of heart failure during treatment with Remicade.
Croatian: Odmah obavijestite svog liječnika ako dobijete nove simptome zatajenja srca ili se postojeći simptomi pogoršaju tijekom liječenja lijekom Remicade.
English: In patients receiving anti-TNF therapy, limited data are available on the response to vaccination with live vaccines or on the secondary transmission of infection by live vaccines.
Croatian: Ograničeni su podaci o odgovoru na cijepljenje živim cjepivima ili o sekundarnom prijenosu infekcije živim cjepivom u bolesnika koji primaju anti-TNF terapiju.
English: How much Remicade is given
Croatian: Koliko lijeka Remicade ćete primiti
English: • Feeling tired or weak
Croatian: • osjećaj utrnulosti i trnci
English: Moderately to severely active Crohn's disease
Croatian: Umjerena do teška, aktivna Crohnova bolest
English: Improvements in quality of life measures, a reduction in disease-related hospitalisations and corticosteroid use were seen in the infliximab maintenance groups compared with the placebo maintenance group at weeks 30 and 54.
Croatian: U odnosu na skupinu koja je primala placebo, u skupinama koje su primale infliksimab kao terapiju održavanja opaženo je poboljšanje u mjerilima kvalitete života, smanjenje hospitalizacija zbog bolesti te smanjena primjena kortikosteroida u 30. i 54. tjednu ispitivanja.
English: Infliximab (week 98)
Croatian: Infliksimab (98. tjedan)
English: Induction treatment in moderately to severely active Crohn's disease The efficacy of a single dose treatment with infliximab was assessed in 108 patients with active Crohn's disease (Crohn's Disease Activity Index (CDAI) ≥ 220 ≤ 400) in a randomised, double-blinded, placebo-controlled, dose-response study.
Croatian: Djelotvornost liječenja jednokratnom dozom infliksimaba ispitana je u 108 bolesnika s aktivnom Crohnovom bolešću (indeks aktivnosti Crohnove bolesti, engl.
English: If a patient does not respond after 2 doses, no additional treatment with infliximab should be given.
Croatian: Ako bolesnik ne odgovori na terapiju nakon 2 doze, ne bi trebalo nastaviti daljnje liječenje infliksimabom.
English: Infusion-related reactions
Croatian: Reakcije vezane uz infuziju
English: Peripheral blood lymphocytes further showed no significant decrease in number or in proliferative responses to in vitro mitogenic stimulation when compared with untreated patients' cells.
Croatian: U odnosu na stanice neliječenih bolesnika nije opaženo značajno smanjenje broja limfocita u perifernoj krvi bolesnika koji su primali infliksimab niti njihovog proliferativnog odgovora na mitogenu stimulaciju in vitro.
English: Clinical remission and mucosal healing occurred in a greater proportion of patients in the combined infliximab treatment group compared to the placebo treatment group at week 54 (34.6% vs. 16.5%, p < 0.001 and 46.1% vs. 18.2%, p < 0.001, respectively).
Croatian: U skupinama liječenima infliksimabom (zbirni podaci) u 54. je tjednu zabilježen veći udio bolesnika u kliničkoj remisiji u odnosu na skupinu koja je primala placebo (34,6% naspram 16,5%, p < 0,001), kao i veći udio bolesnika u kojih je nastupilo cijeljenje sluznice (46,1% liječenih infliksimabom naspram 18,2% bolesnika koji su primali placebo, p < 0,001).
English: • Serious nervous system disorders such as transverse myelitis, multiple sclerosis-like disease,
Croatian: • ozbiljni poremećaji živčanog sustava kao što su poprečni mijelitis, bolesti nalik multiploj sklerozi, optički neuritis i Guillain-Barréov sindrom
English: In the post-marketing setting, cases of leukaemia have been reported in patients treated with a TNF-antagonist.
Croatian: U razdoblju nakon stavljanja lijeka u promet u bolesnika liječenih TNF-antagonistom prijavljeni su slučajevi leukemije.
English: Paediatric ulcerative colitis patients
Croatian: Ulcerozni kolitis u pedijatrijskih bolesnika
English: • Lung problems (such as oedema)
Croatian: • tegobe s plućima (poput edema)
English: The duration of subsequent infusions could be shortened to not less than 40 minutes in patients who did not experience serious infusion reactions.
Croatian: U bolesnika koji nisu imali ozbiljne reakcije na infuziju trajanje sljedećih infuzija moglo se smanjiti na najmanje 40 minuta.
English: Tell your doctor straight away if you get symptoms of low blood counts during treatment with Remicade.
Croatian: Odmah obavijestite Vašeg liječnika ako dobijete simptome smanjenog broja krvnih stanica za vrijeme liječenja lijekom Remicade.
English: Infliximab treatment reduced the rate of progression of peripheral joint damage compared with placebo treatment at the week 24 primary endpoint as measured by change from baseline in total modified vdH-S score (mean ± SD score was 0.82 ± 2.62 in the placebo group compared with -0.70 ± 2.53 in the infliximab group; p < 0.001).
Croatian: Sudeći prema promjeni u ukupnom rezultatu po van der Heijdeu modificiranoj Sharpovoj bodovnoj skali u odnosu na početno stanje (prosječan rezultat ± SD bio je 0,82 ± 2,62 u skupini koja je primala placebo, dok je u skupini koja je primala infliksimab iznosio -0,70 ± 2,53; p < 0,001), liječenje infliksimabom je u odnosu na placebo smanjilo brzinu napredovanja oštećenja perifernih zglobova, što je bila primarna mjera ishoda u 24. tjednu.
English: Discard this medicine if not used by the new expiry date or the expiry date printed on the carton, whichever is earlier.
Croatian: Ako ga ne uporabite do novog roka valjanosti ili roka valjanosti otisnutog na kutiji, ovisno o tome koji je raniji, lijek bacite.
English: • Side effect due to an infusion
Croatian: • nuspojava kao posljedica infuzije • bol
English: If you have ankylosing spondylitis you will first be given other medicines.
Croatian: Ako imate aktivni ankilozantni spondilitis, najprije ćete dobiti druge lijekove.
English: Do not use if visibly opaque particles, discolouration or foreign particles are observed.
Croatian: Ne koristite otopinu ako se vide neprozirne ili kakve druge strane čestice ili ako promijeni boju.
English: How Remicade is given
Croatian: Kako se primjenjuje Remicade
English: The solution may develop a few fine translucent particles, as infliximab is a protein.
Croatian: Budući da je infliksimab protein, u otopini se može stvoriti nekoliko sitnih prozirnih čestica.
English: Table 4 Effects on ACRn, Structural Joint Damage and Physical Function at week 54, ASPIRE Infliximab + MTX Placebo + MTX 3 mg/kg 6 mg/kg Combined
Croatian: Placebo + MTX 3 mg/kg 6 mg/kg Kombinirano
English: ** PASI 75 response for IMPACT not included due to low N; p < 0.001 for infliximab vs. placebo at week 24 for IMPACT 2.
Croatian: Na temelju broja bolesnika s početnim PASI ≥ 2,5 u ispitivanju IMPACT i bolesnika s početnom zahvaćenošću kože psorijazom ≥ 3% BSA u ispitivanju IMPACT 2. ** Odgovor PASI 75 u ispitivanju IMPACT nije uključen zbog malog N; p < 0,001 za infliksimab u usporedbi s placebom u 24. tjednu ispitivanja IMPACT 2.
English: All patients received an induction regimen of 5 mg/kg infliximab at weeks 0, 2, and 6.
Croatian: Svi su bolesnici primili uvodni režim liječenja infliksimabom u dozi od 5 mg/kg u 0., 2. i 6. tjednu.
English: Peripheral blood mononuclear cells (PBMC) from infliximab-treated patients showed undiminished proliferative responsiveness to stimuli compared with untreated patients, and no substantial changes in cytokine production by stimulated PBMC were observed following treatment with infliximab.
Croatian: Mononuklearne stanice u perifernoj krvi bolesnika liječenih infliksimabom pokazale su neumanjenu proliferativnu sposobnost odgovora na stimulaciju u odnosu na neliječene bolesnike.
English: • Liver failure
Croatian: • zatajenje jetre
English: • Kidney infections
Croatian: • infekcije mokraćnih puteva
English: Rare: Transverse myelitis, central nervous system demyelinating disorders (multiple sclerosis-like disease and optic neuritis), peripheral demyelinating disorders (such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy).
Croatian: Često: depresija, nesanica Manje često: amnezija, agitacija, konfuzija, somnolencija, nervoza Rijetko: apatija Poremećaji živčanog sustava Vrlo često: glavobolja Često: vrtoglavica, omaglica, hipoestezija, parestezija Manje često: napadaji, neuropatija Rijetko: transverzalni mijelitis, demijelinizacijski poremećaji središnjeg živčanog sustava (bolest nalik multiploj sklerozi i optički neuritis), demijelinizacijski poremećaji perifernog živčanog sustava (kao što su Guillain-Barréov sindrom, kronična upalna demijelinizacijska polineuropatija i multifokalna motorička neuropatija)
English: Cases of jaundice and non-infectious hepatitis, some with features of autoimmune hepatitis, have been observed in the post-marketing experience of Remicade.
Croatian: Nakon stavljanja lijeka Remicade u promet, primijećeni su slučajevi žutice i neinfektivnog hepatitisa, koji je ponekad imao značajke autoimunog hepatitisa.
English: Overall, 8 (13.3%) of 60 treated patients experienced one or more infusion reactions, with 4 of 22 (18.2%) in the q8 week and 3 of 23 (13.0%) in the q12 week treatment maintenance group.
Croatian: Reakcije su se javile u 4 od 22 bolesnika (18,2%) u skupini koja je terapiju održavanja primala svakih 8 tjedana te u 3 od 23 bolesnika (13,0%) koji su terapiju primali svakih 12 tjedana.
English: Rare: Agranulocytosis (including infants exposed in utero to infliximab), thrombotic thrombocytopenic purpura, pancytopenia, haemolytic anaemia, idiopathic thrombocytopenic purpura.
Croatian: Često: neutropenija, leukopenija, anemija, limfadenopatija Manje često: trombocitopenija, limfopenija, limfocitoza Rijetko: agranulocitoza (uključujući dojenčad izloženu infliksimabu in utero), trombotička trombocitopenična purpura, pancitopenija, hemolitička anemija, idiopatska trombocitopenična purpura
English: If a patient does not respond after 3 doses, no additional treatment with infliximab should be given.
Croatian: Ako bolesnik ne odgovori na terapiju nakon 3 doze, ne bi trebalo nastaviti liječenje infliksimabom.
English: 4 vials 100 mg
Croatian: 4 bočice sa 100 mg
English: After reconstitution each ml contains 10 mg of infliximab.
Croatian: Nakon rekonstitucije, 1 ml sadrži 10 mg infliksimaba.
English: At week 12, placebo patients were switched to infliximab 5 mg/kg every 6 weeks up to week 54.
Croatian: Bolesnici koji su primali placebo počeli su u 12. tjednu umjesto placeba primati infliksimab u dozi od 5 mg/kg svakih 6 tjedana tijekom ukupno 54 tjedna.
English: Mean ± SD
Croatian: Prosječna vrijednost ± SD
English: At week 8, 45 patients were randomised and received 5 mg/kg infliximab at either q8 weeks or q12 weeks as a maintenance treatment regimen.
Croatian: U 8. je tjednu 45 bolesnika randomizirano na terapiju održavanja infliksimabom u dozi od 5 mg/kg svakih 8 tjedana ili svakih 12 tjedana.
English: • Skin problems such as blistering, warts, abnormal skin colouration or pigmentation, or swollen lips, or thickening of the skin, or red, scaly, and flaky skin
Croatian: oticanje usana, zadebljanje kože ili crvena, ljuskava i perutava koža
English: Patients randomised 52
Croatian: Randomizirani bolesnici
English: Table 10 Summary of PASI response, PGA response and percent of patients with all nails cleared at weeks 10, 24 and 50.
Croatian: Tablica 10 Sažeti prikaz PASI odgovora, PGA odgovora i postotka bolesnika bez psorijatičnih promjena na noktima u 10., 24. i 50. tjednu, EXPRESS Placebo → infliksimab 5 mg/kg (u 24. tjednu)
English: • You have heart failure that is moderate or severe.
Croatian: • Ako imate umjeren ili težak stupanj zatajenja srca.
English: 3 mg/kg given as an intravenous infusion followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter.
Croatian: Daje se doza od 3 mg/kg intravenskom infuzijom, a zatim slijede dodatne infuzije u dozi od 3 mg/kg u 2. i 6. tjednu nakon prve infuzije te svakih 8 tjedana nakon toga.
English: 2 vials 100 mg
Croatian: 2 bočice sa 100 mg
English: Paediatric Crohn's disease patients
Croatian: Crohnova bolest u pedijatrijskih bolesnika
English: Liver problems
Croatian: Jetrene tegobe
English: • Wounds taking longer to heal
Croatian: • otežano zacjeljivanje rana
English: Adult psoriasis
Croatian: Psorijaza u odraslih bolesnika
English: Juvenile rheumatoid arthritis patients
Croatian: Bolesnici s juvenilnim reumatoidnim artritisom
English: • Severely decreased numbers of white blood cells have been reported in infants born to women treated with Remicade during pregnancy.
Croatian: • U dojenčadi čije su majke tijekom trudnoće liječene lijekom Remicade prijavljeno je značajno smanjenje bijelih krvnih stanica.
English: Had treatment with Remicade before
Croatian: Prethodno liječenje lijekom Remicade
English: Adult Crohn's disease Remicade is indicated for:
Croatian: Kod primjene lijeka Remicade opažene su sljedeće nuspojave:
English: 5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusions at 2 and 6 weeks after the first infusion.
Croatian: Daje se doza od 5 mg/kg intravenskom infuzijom, a zatim slijede dodatne infuzije u dozi od 5 mg/kg u 2. i 6. tjednu nakon prve infuzije.
English: Infliximab Monotherapy
Croatian: Monoterapija infliksimabom
English: Tell your doctor straight away if you get symptoms of liver problems during treatment with Remicade.
Croatian: Odmah obavijestite Vašeg liječnika ako dobijete simptome jetrenih tegoba za vrijeme liječenja lijekom Remicade.
English: Reproductive system and breast disorders
Croatian: Poremećaji bubrega i mokraćnog sustava
English: Do not use if opaque particles, discolouration, or other foreign particles are present.
Croatian: Ne koristite otopinu ako se u njoj pojave neprozirne ili kakve druge strane čestice ili ako promijeni boju.
English: 3 vials 100 mg
Croatian: 3 bočice sa 100 mg
English: A risk for the development of malignancies in patients treated with TNF-blockers cannot be excluded.
Croatian: U bolesnika koji se liječe TNF-blokatorima ne može se isključiti rizik od razvoja zloćudnih bolesti.
English: 10 mg/kg q 8 wks
Croatian: 10 mg/kg svakih 8 tjedana
English: Adult ankylosing spondylitis
Croatian: Ankilozantni spondilitis u odraslih bolesnika
English: Monobasic sodium phosphate Dibasic sodium phosphate
Croatian: 6.1 Popis pomoćnih tvari saharoza polisorbat 80 natrijev dihidrogenfosfat natrijev hidrogenfosfat
English: Infliximab does not cross react with TNF from species other than human and chimpanzees.
Croatian: Infliksimab pokazuje križnu reakciju samo s TNFα ljudi i čimpanza, ali ne i drugih vrsta, stoga su konvencionalni neklinički podaci o sigurnosti primjene lijeka ograničeni.
English: nd dose
Croatian: 3. doza
English: Each Remicade vial contains 100 mg infliximab.
Croatian: Jedna bočica sadrži 100 mg infliksimaba.
English: Patients received either 3 or 5 mg/kg infliximab or placebo infusions at weeks 0, 2 and 6.
Croatian: Bolesnici su primili infuzije infliksimaba u dozi od 3 mg/kg odnosno 5 mg/kg ili placeba u 0., 2. i 6. tjednu.
English: In patients treated with Remicade, an invasive fungal infection such as aspergillosis, candidiasis, pneumocystosis, histoplasmosis, coccidioidomycosis or blastomycosis should be suspected if they develop a serious systemic illness, and a physician with expertise in the diagnosis and treatment of invasive fungal infections should be consulted at an early stage when investigating these patients.
Croatian: U bolesnika liječenih lijekom Remicade u kojih se razvije ozbiljna sistemska bolest treba posumnjati na neku invazivnu gljivičnu infekciju poput aspergiloze, kandidijaze, pneumocistoze, histoplazmoze, kokcidioidomikoze ili blastomikoze.
English: The following side effects have been observed with Remicade:
Croatian: Remicade je indiciran za:
English: Uncommon: Hepatitis, hepatocellular damage, cholecystitis.
Croatian: Manje često: hepatitis, hepatocelularna oštećenja, kolecistitis Rijetko: autoimuni hepatitis, žutica Nepoznato: zatajenje jetre
English: Discontinuation of Remicade therapy should be considered in patients with confirmed significant haematologic abnormalities.
Croatian: U bolesnika s potvrđenim značajnim hematološkim poremećajima treba razmotriti prekid liječenja lijekom Remicade.
English: 5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks.
Croatian: Daje se doza od 5 mg/kg intravenskom infuzijom, a zatim slijede dodatne infuzije u dozi od 5 mg/kg u 2. i 6. tjednu nakon prve infuzije te svakih 6 do 8 tjedana nakon toga.
English: • You should receive recommended vaccinations before starting Remicade treatment.
Croatian: • Prije početka liječenja lijekom Remicade trebate primiti sva preporučena cjepiva.
English: Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed taking into account both the risk for severe fungal infection and the risks of antifungal therapy.
Croatian: Uzimajući u obzir rizike invazivne gljivične infekcije kao i rizike antimikotičke terapije, treba razmotriti primjenu odgovarajuće empirijske antimikotičke terapije tijekom dijagnostičkog postupka.
English: In patients who have several or significant risk factors for tuberculosis and have a negative test for latent tuberculosis, antituberculosis therapy should be considered before the initiation of Remicade.
Croatian: Treba razmotriti primjenu antituberkulozne terapije prije početka liječenja lijekom Remicade u bolesnika koji imaju brojne ili značajne čimbenike rizika za tuberkulozu, a rezultati testa na latentnu tuberkulozu su im negativni.
English: 5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter.
Croatian: Daje se doza od 5 mg/kg intravenskom infuzijom, a zatim slijede dodatne infuzije u dozi od 5 mg/kg u 2. i 6. tjednu nakon prve infuzije te svakih 8 tjedana nakon toga.
English: Control
Croatian: Kontrolna skupina
English: or boils (furunculosis)
Croatian: • oticanje gušterače (upala gušterače)
English: Adult psoriatic arthritis
Croatian: Psorijatični artritis u odraslih bolesnika
English: Tell your doctor straight away if you get signs of infection during treatment with Remicade.
Croatian: Odmah obavijestite svog liječnika ako tijekom liječenja lijekom Remicade dobijete simptome infekcije.
English: 5 mg/kg given as an intravenous infusion followed by an additional 5 mg/kg infusion 2 weeks after the first infusion.
Croatian: Daje se doza od 5 mg/kg intravenskom infuzijom, a zatim se 2 tjedna nakon prve infuzije daje dodatna infuzija u dozi od 5 mg/kg.
English: Starting at week 16, placebo patients were switched to infliximab and all patients subsequently received 5 mg/kg infliximab every 8 weeks up to week 46.
Croatian: Od 16. tjedna nadalje bolesnici koji su primali placebo počeli su dobivati infliksimab, tako da su do kraja 46. tjedna svi bolesnici dobivali dozu od
English: Foaming of the solution on reconstitution is not unusual.
Croatian: Nije neobično ako se otopina zapjeni.
English: Sustained response (clinical response at both week 8 and week 30)
Croatian: Održani odgovor (klinički odgovor i u
English: IV
Croatian: D.
English: Tell your doctor straight away if you get symptoms of a nerve disease during treatment with Remicade.
Croatian: Odmah obavijestite svog liječnika ako tijekom liječenja lijekom Remicade dobijete simptome neke bolesti živčanog sustava.